Nektar Therapeutics (NKTR) Assets Average (2011 - 2026)

Nektar Therapeutics' Assets Average history runs 16 years deep, the most recent figure standing at $521.8 million for Q1 2026.

• On a quarterly basis, Assets Average rose 86.34% year-over-year to $521.8 million in Q1 2026; TTM through Mar 2026 was $521.8 million, a 86.34% increase from a year earlier, with the FY2025 full-year figure at $292.1 million, down 16.76% from the prior year.
• Assets Average grew to $521.8 million in Q1 2026 per NKTR's latest filing, from $290.9 million in the prior quarter.
• Across five years, Assets Average topped out at $1.1 billion in Q1 2022 and bottomed at $231.9 million in Q2 2025.
• The 5-year median for Assets Average is $420.1 million (2023), against an average of $506.5 million.
• Across the five-year window, Assets Average slumped 44.01% in 2023 and surged 86.34% in 2026, its largest moves.
• Year by year, Assets Average stood at $745.8 million in 2022, then sank by 43.67% to $420.1 million in 2023, then fell by 27.19% to $305.9 million in 2024, then dropped by 4.91% to $290.9 million in 2025, then jumped by 79.4% to $521.8 million in 2026.
• Per Business Quant, the three latest NKTR Assets Average figures stand at $521.8 million (Q1 2026), $290.9 million (Q4 2025), and $254.4 million (Q3 2025).